FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067066175> ?p ?o ?g. }

• W2067066175 endingPage "62" @default.
• W2067066175 startingPage "58" @default.
• W2067066175 abstract "Neuroendocrine differentiation in carcinoma of the prostate is characterized by the expression of neuroendocrine cell products such as chromogranin A (CgA). We studied serum levels and tissue staining for CgA in prostate cancer to assess their clinical value.In 82 patients with prostate cancer, serum specimens were obtained at diagnosis and studied by both CgA and prostate-specific antigen (PSA) immunoassays. In 43 additional patients with prostate cancer, paraffin-embedded tissue from core biopsies or transurethral resections and serum samples were studied, respectively, by immunohistology and immunoassay for CgA.In serum samples from the 82 patients in whom CgA and PSA levels were measured, 26 of 82 (32%) had an elevated CgA (greater than 200 ng/mL), and 36 of 82 (44%) had an elevated PSA (greater than 4.0 ng/mL). Of the patients with Stage D2 cancer, 11 of 18 (61%) had an elevated CgA and 6 of 18 (33%) had an elevated PSA. Four of 5 patients with local recurrence had an elevated CgA, but only 1 patient had an elevated PSA. Of the 43 patients in whom serum and tissue CgA studies were performed, 12 (28%) had elevated serum CgA, and 15 of the 43 (35%) had CgA staining in their prostate tissue. Of the 14 of these patients with D2 disease (distant metastases), 9 (64%) had elevated serum levels of CgA and 6 (43%) had positive staining in their prostate tissue. Of the 9 patients with Stage D2 disease and elevated serum CgA, 6 had a normal serum PSA.Our studies complement those of others and indicate that CgA has potential as a clinically useful serum and tumor marker for prostate cancer. Serum CgA measurements can identify some patients with advanced disease who do not have elevated serum PSA. However, further studies in larger groups of patients are needed to define the clinical value of CgA as a marker for prostate cancer." @default.
• W2067066175 created "2016-06-24" @default.
• W2067066175 creator A5043570965 @default.
• W2067066175 creator A5077067684 @default.
• W2067066175 creator A5080149796 @default.
• W2067066175 creator A5088158867 @default.
• W2067066175 creator A5088354027 @default.
• W2067066175 creator A5091013256 @default.
• W2067066175 date "1996-07-01" @default.
• W2067066175 modified "2023-09-23" @default.
• W2067066175 title "Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate" @default.
• W2067066175 cites W1964279511 @default.
• W2067066175 cites W1982195270 @default.
• W2067066175 cites W1991649929 @default.
• W2067066175 cites W1994355495 @default.
• W2067066175 cites W1995328990 @default.
• W2067066175 cites W2004764616 @default.
• W2067066175 cites W2030167821 @default.
• W2067066175 cites W2030716693 @default.
• W2067066175 cites W2046063243 @default.
• W2067066175 cites W2046349824 @default.
• W2067066175 cites W2050713927 @default.
• W2067066175 cites W2083288994 @default.
• W2067066175 cites W2088482523 @default.
• W2067066175 cites W2093671803 @default.
• W2067066175 cites W2139258764 @default.
• W2067066175 cites W2162784961 @default.
• W2067066175 cites W2201035906 @default.
• W2067066175 cites W2319457872 @default.
• W2067066175 cites W2342163288 @default.
• W2067066175 cites W2417434595 @default.
• W2067066175 cites W74496888 @default.
• W2067066175 doi "https://doi.org/10.1016/s0090-4295(96)00089-1" @default.
• W2067066175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8693652" @default.
• W2067066175 hasPublicationYear "1996" @default.
• W2067066175 type Work @default.
• W2067066175 sameAs 2067066175 @default.
• W2067066175 citedByCount "83" @default.
• W2067066175 countsByYear W20670661752012 @default.
• W2067066175 countsByYear W20670661752013 @default.
• W2067066175 countsByYear W20670661752014 @default.
• W2067066175 countsByYear W20670661752017 @default.
• W2067066175 countsByYear W20670661752019 @default.
• W2067066175 crossrefType "journal-article" @default.
• W2067066175 hasAuthorship W2067066175A5043570965 @default.
• W2067066175 hasAuthorship W2067066175A5077067684 @default.
• W2067066175 hasAuthorship W2067066175A5080149796 @default.
• W2067066175 hasAuthorship W2067066175A5088158867 @default.
• W2067066175 hasAuthorship W2067066175A5088354027 @default.
• W2067066175 hasAuthorship W2067066175A5091013256 @default.
• W2067066175 hasConcept C121608353 @default.
• W2067066175 hasConcept C126322002 @default.
• W2067066175 hasConcept C126894567 @default.
• W2067066175 hasConcept C142724271 @default.
• W2067066175 hasConcept C146357865 @default.
• W2067066175 hasConcept C151730666 @default.
• W2067066175 hasConcept C159654299 @default.
• W2067066175 hasConcept C203014093 @default.
• W2067066175 hasConcept C204232928 @default.
• W2067066175 hasConcept C2776235491 @default.
• W2067066175 hasConcept C2777546739 @default.
• W2067066175 hasConcept C2780192828 @default.
• W2067066175 hasConcept C2780341458 @default.
• W2067066175 hasConcept C2780420688 @default.
• W2067066175 hasConcept C2781406297 @default.
• W2067066175 hasConcept C71924100 @default.
• W2067066175 hasConcept C74864618 @default.
• W2067066175 hasConcept C77231918 @default.
• W2067066175 hasConcept C86803240 @default.
• W2067066175 hasConcept C87874733 @default.
• W2067066175 hasConcept C90924648 @default.
• W2067066175 hasConceptScore W2067066175C121608353 @default.
• W2067066175 hasConceptScore W2067066175C126322002 @default.
• W2067066175 hasConceptScore W2067066175C126894567 @default.
• W2067066175 hasConceptScore W2067066175C142724271 @default.
• W2067066175 hasConceptScore W2067066175C146357865 @default.
• W2067066175 hasConceptScore W2067066175C151730666 @default.
• W2067066175 hasConceptScore W2067066175C159654299 @default.
• W2067066175 hasConceptScore W2067066175C203014093 @default.
• W2067066175 hasConceptScore W2067066175C204232928 @default.
• W2067066175 hasConceptScore W2067066175C2776235491 @default.
• W2067066175 hasConceptScore W2067066175C2777546739 @default.
• W2067066175 hasConceptScore W2067066175C2780192828 @default.
• W2067066175 hasConceptScore W2067066175C2780341458 @default.
• W2067066175 hasConceptScore W2067066175C2780420688 @default.
• W2067066175 hasConceptScore W2067066175C2781406297 @default.
• W2067066175 hasConceptScore W2067066175C71924100 @default.
• W2067066175 hasConceptScore W2067066175C74864618 @default.
• W2067066175 hasConceptScore W2067066175C77231918 @default.
• W2067066175 hasConceptScore W2067066175C86803240 @default.
• W2067066175 hasConceptScore W2067066175C87874733 @default.
• W2067066175 hasConceptScore W2067066175C90924648 @default.
• W2067066175 hasIssue "1" @default.
• W2067066175 hasLocation W20670661751 @default.
• W2067066175 hasLocation W20670661752 @default.
• W2067066175 hasOpenAccess W2067066175 @default.
• W2067066175 hasPrimaryLocation W20670661751 @default.
• W2067066175 hasRelatedWork W1877031100 @default.

• next